Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TheraTech (THRT) -- Ignore unavailable to you. Want to Upgrade?

To: Mike Hagerty who wrote (118)	9/28/1998 2:43:00 PM
From: geoffrey Wren	Read Replies (1) \| Respond to of 125

Company press release: Tuesday September 22, 8:06 am Eastern Time Company Press Release TheraTech Receives Federal Grant To Study Innovative Rheumatoid Arthritis Therapy SALT LAKE CITY--(BW HealthWire)--Sept. 22, 1998--TheraTech Inc. (Nasdaq:THRT - news) Tuesday announced receipt of a National Institutes of Health (NIH) grant that will fund initial studies of an innovative therapy for rheumatoid arthritis. The grant, awarded under the NIH Small Business Innovation Research Program, will support a study utilizing TheraTech's peptide-based cell-targeted system to deliver cytotoxic and/or immunosuppressant drugs directly to immune cells for the treatment of rheumatoid arthritis. Ramesh Prakash, Ph.D., TheraTech's director of biotechnology research and development, will be the principal investigator on the study. According to Dr. Prakash, the study is designed to demonstrate that TheraTech's proprietary technology can deliver drugs directly to immune cells activated in rheumatoid arthritis. ''This approach may mitigate the immune response and resultant tissue destruction associated with rheumatoid arthritis, while avoiding non-specific toxicities that may occur with conventional systemic dosing,'' Dr. Prakash stated. Dinesh C. Patel, Ph.D., TheraTech's chairman, president and chief executive officer, noted that this is one of several cell-targeted drug delivery studies that the company has underway. ''TheraTech is actively developing a number of cell-targeted therapeutic treatments for cancer, auto-immune, and other immune system-related diseases,'' he said. TheraTech Inc. is a leading drug delivery company that develops, manufactures, and markets innovative products based on its patented and proprietary delivery products and systems. These include a variety of transdermal patches, oral transmucosal systems for delivery of peptides and other drugs requiring rapid onset (i.e. pain medications), oral controlled-release systems, topical preparations, and cell-targeted drug delivery technologies. The company has four products on the market, over 20 products in its development pipeline and holds 50 issued, allowed, and/or pending U.S. patents, with international counterparts granted and/or filed. TheraTech has research, development and/or marketing agreements with leading multi-national as well as regional pharmaceutical companies, including: Eli Lilly, Procter & Gamble, Pfizer, SmithKline Beecham, Wyeth-Ayerst, Astra, CEPA, Lavipharm S.A., Schwarz Pharma AG, Meiji, Samyang and Sankyo. For additional information, visit TheraTech Inc.'s Web Site at www.thrt.com, or e-mail information requests to: Investor@thrt.com Statements contained in this release that are not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements of TheraTech's beliefs, expectations, hopes or intentions regarding the future. All forward-looking statements included in this release are made as of the date hereof and are based on information available to TheraTech as of such date. TheraTech assumes no obligation to update any forward-looking statement. It is important to note that actual outcomes and TheraTech's actual results could differ materially from those in such forward-looking statements. Readers and editors should refer to the risks and other disclosures outlined in TheraTech's filings with the Securities and Exchange Commission on Forms 10-K and 10-Q.